Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.

Slides:

Advertisements

Similar presentations

HYPnet Late presentation of vertically transmitted HIV infection in adolescence A Judd 1, R Ferrand 2,3, E Jungmann 2, C Foster 4, H Lyall 4, Brian Rice.

Advertisements

Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):

The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.

Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.

Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,

Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,

PMTCT program in Arua Uganda Lessons learned after 5 years of experience Experts Roundtable June 2008 Geneva.

Perinatal HIV Case Series Reports for Births in Presenter: Elvia Ledezma Texas Department of State Health Services.

Late HIV Diagnoses, Georgia,

THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2014* * Numbers are based on reports received rather than children seen to.

BHIVA national clinical audit of HIV diagnosis Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical.

Tuberculosis in the UK 2013 report

HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,

Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.

Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,

Africans and HIV in the UK: an epidemiological perspective Nov 2006 Tim Chadborn On behalf of the HIV Reporting Section with special thanks to Julia Abernethy.

Long term follow up of the UK and Ireland paediatric cohort as teenagers transition to adult services Ali Judd, 1 Caroline Foster, 2 Caroline Sabin, 3.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2013* * Numbers are based on reports received rather than children seen to.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

Pediatric ID Previous presentation by Susan Schuval, MD

BHIVA national clinical audit of ART Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical audit committee.

C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.

Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.

Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Determinants of long term adherence to antiretroviral drugs among adults followed over 54 months in Dakar (Senegal) M. Ciss 1, A. Desclaux 2, K. Diop 3,

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.

HIV Care Continuum Persons Living With HIV, Georgia, 2012.

Data Management and Analysis Baljit Bains and Ed Klodawski Demography Team Data Management and Analysis Group Ethnic Group Fertility Rates for London using.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2012* * Numbers are based on reports received rather than children seen to.

CONCLUSIONS  Mortality and hospital admission rates continued to decline since the introduction of HAART in 1997  Viral load suppression 12 months after.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,

Annual Epidemiological Spotlight on HIV in London: 2014 data Field Epidemiology Services PHE Publications gateway number

HIV surveillance in Northern Ireland 2013 An analysis of data for the calendar year 2012.

MINNESOTA’S HIV TREATMENT CASCADE April, Introduction.

Retention in care and connection to care among HIV-infected patients receiving ART n Africa: Estimation via a sampling-based approach Elvin Geng 1, David.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent

Viral load distribution 2012 among persons living with HIV and persons newly diagnosed Georgia, 2011.

Exposure and response to highly active antiretroviral therapy (HAART) in ART naïve children in the UK and Ireland Judd A. 1, Lee K.J. 1, Duong T. 1, Walker.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Africans and HIV in the UK: an epidemiological perspective May 2006 Valerie Delpech On behalf of the HIV Reporting Section with special thanks to Julia.

A Call to Action Children – The missing face of AIDS.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to June 2015* * Numbers are based on reports received rather than children seen to.

MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.

Seroprevalence and vaccination of measles, varicella and rubella in adolescents with vertically acquired HIV infection: a multicentre audit Elgalib A 1,2,

Malignancies in Young People Sophie Herbert, Alison Barbour, Eva Jungmann, Caroline Foster on behalf of the HIV Young Persons Network (HYPNET)

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.

Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:

Loss to follow-up of HIV-infected women after delivery: The Swiss Mother and Child HIV Cohort Study Karoline Aebi-Popp, Roger Kouyos, Barbara Bertisch,

Obstetric and paediatric HIV surveillance data from the UK and Ireland

HIV surveillance in Northern Ireland 2014

Obstetric and paediatric HIV surveillance data from the UK and Ireland

Obstetric and paediatric HIV surveillance data from the UK and Ireland

Obstetric and paediatric HIV surveillance data from the UK and Ireland

January 2014 Update Obstetric and paediatric HIV surveillance data from the UK and Ireland.

Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2

Collaborative HIV Paediatric Study

HIV surveillance in Northern Ireland 2018

Presentation transcript:

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005

Background for CHIPS The Collaborative HIV Paediatric Study (CHIPS) was established in April 2000 as a multi-centre cohort study of HIV infected children in the UK and Ireland. The collaboration is between 25 centres in the UK and Ireland that care for HIV-infected children, many of whom are enrolled in PENTA trials the National Study of HIV in Pregnancy and Childhood (NSHPC), and the MRC Clinical Trials Unit

Follow-up status of 994 children enrolled in CHIPS

Age and year at first presentation to medical services in UK (N=994) Up to At birth 100(12%) 9( 8%) 3( 6%) 0 <1 yr 225(27%) 12(11%) 9(17%) yrs 289(35%) 24(21%) 16(31%) yrs 151(18%) 45(40%) 15(29%) 3 >=10 yrs 62( 8%) 22(20%) 9(17%) 0 Total

Year No in Median age Age groups follow-up (IQR) <1 yr 1-4 yrs 5-9 yrs  10 yrs ( ) 47(14%) 141(42%) 118(35%) 30(9%) ( ) 58(15%) 142(37%) 145(38%) 39(10%) ( ) 56(12%) 166(36%) 173(38%) 61(13%) ( ) 43(8%) 176(34%) 204(40%) 91(18%) ( ) 39(7%) 188(32%) 230(39%) 127(22%) ( ) 38(6%) 187(29%) 247(38%) 179(27%) ( ) 37(5%) 178(25%) 279(39%) 224(31%) ( ) 37(5%) 160(20%) 328(41%) 277(35%) ( ) 29(4%) 139(17%) 315(39%) 317(40%) Age distribution of children in follow-up over calendar time * Age is taken to be age at start of the year, or age at presentation if child presented during that year

All hospital admissions during Year Number Number Proportion Total Rate children children admitted number (# adm per seen admitted (%) admissions pyar) Admissions may be underreported for children in shared care where only information from the main CHIPS follow-up centre are reported. Data for 2004 are incomplete and are not presented.

HIV RNA viral load at 6 months after starting HAART as first line therapy N=434 with measurements available (96 missing) Year HIV RNA (copies/ml) (20%) 58 (36%) 70 (44%) 2000/02 47 (30%) 59 (37%) 52 (33%) (59%) 25 (22%) 22 (19%) Total 148 (34%) 142 (33%) 144 (33%)

Data on 818 children who are still alive and in follow-up (794 in CHIPS centres and 24 who have transferred to non-CHIPS centres) Those who have died, lost to follow-up, left the UK & Ireland or transferred to adult care are excluded

Demographic Data (N=818) * Data provided by NSHPC - 418(51%) are female - 450(55%) born UK/Ireland, 366(45%) born abroad (2 missing) - Ethnicity White 87 (11%) Black African 611 (75%) Black Other 12 (1%) Indian SC 11 (1%) Mixed 84 (10%) Other 7 (1%) Not known 6 (1%) - Diagnosis of maternal infection (N=777 vertically infected) Known after delivery 650 (84%) Known before delivery 111 (14%) Not known 16 (2%)

636 (78%) London 18 (2%) Scotland 98 (12%) Rest of England 58 (8%) Ireland 8 (1%) Wales Regional distribution of main follow-up centre for 818 children alive and followed up in CHIPS Children who have died, lost to follow-up, left the UK & Ireland or transferred to adult care are excluded

Year of last follow-up (N=818)

Clinical stage by age at last follow-up (N=818) Number of children:Total (col %) (42%) (29%) (29%)

Antiretroviral drug experience N=802 children with follow-up since January 2003 Number of children:Total (col %) (24%) (43%) (23%) (10%)

ART at last follow-up N=526 children with follow-up since Jan 2003 were on treatment 7 on dual, 449 on 3-drug, 67 on 4-drug and 3 on 5(+)-drug therapy

Most recent CD4% (N=794) Children followed up since January 2003

Most recent HIV RNA viral load (N=793) Children followed up since January 2003